Pharma

This detailed response provides comprehensive flashcards for all skeletal muscle relaxants and related pharmaceutical agents mentioned in the sources, organized according to your requested six key points.

***

## Comprehensive Flashcards: Skeletal Muscle Relaxants

### Group 1: Competitive Neuromuscular Blockers (Non-depolarizing)

| Point | Detail |

| :--- | :--- |

| **Generic/Brand Name** | **d-Tubocurarine** (prototype). **Long-acting:** Pancuronium. **Intermediate:** Atracurium, Vecuronium, Rocuronium. **Short-acting:** Mivacurium. |

| **Classification** | Neuromuscular Blockers (NMBs). Post-synaptically acting. **Non-depolarizing** or **Competitive Antagonists**. Highly polar compounds injected intravenously (IV), with **No CNS activity**. |

| **MOA** | **Reversible Competitive Antagonism**: Compete with Acetylcholine (Ach) at the **nicotinic receptors** on the motor end plate. This prevents depolarization, resulting in **no contraction**. At higher doses, they also block $\text{Na}^{+}$ channels, which further weakens neuromuscular transmission. |

| **Clinical Uses** | Used primarily as **adjuvant drugs to general anesthesia** to facilitate incision and produce satisfactory skeletal muscle relaxation. Used to facilitate **endotracheal intubation** (Rocuronium is preferred due to rapid onset). Used to assist **mechanical ventilation**. |

| **Key Side Effects** | Muscle weakness progressing to **flaccid paralysis**. Paralysis sequence: Small rapidly contracting muscles of the face and eye are paralyzed first, and the **diaphragm is paralyzed last**. **d-Tubocurarine** specifically causes **Histamine release** (leading to hypotension, flushing, and bronchoconstriction/bronchospasm). Hypotension and Tachycardia. |

| **Cautions/Contraindications** | Effects are **antagonized/reversed** by **cholinesterase inhibitors** (e.g., Neostigmine, Edrophonium). Neostigmine must be preceded by **Atropine** to block muscarinic receptors and avoid bradycardia/cardiac arrest. **Contraindicated in renal disease** (as many are excreted in urine). Action is **enhanced** by **Halogenated hydrocarbon anesthesia** (like Halothane), **Aminoglycoside antibiotics** (like gentamicin, by competing with $\text{Ca}^{++}$ ions), and **Calcium channel blockers** (like nifedipine). |

***

### Group 2: Depolarizing Neuromuscular Blockers

| Point | Detail |

| :--- | :--- |

| **Generic/Brand Name** | **Succinylcholine (SCh)**. Decamethonium. |

| **Classification** | Neuromuscular Blockers (NMBs). **Depolarizing** or **Non-competitive Antagonists**. Acts as a **Partial Agonist**. |

| **MOA** | **Dual Block (Two Phases)**: **Phase 1 (Depolarization):** Causes disorganized contraction or **fasciculation** (twitching). **Phase 2 (Desensitization):** Persistence of SCh renders the receptor incapable of binding Ach, causing **flaccid paralysis**. |

| **Clinical Uses** | Due to **rapid onset (1 minute)** and **short duration (5–10 minutes)**: Used for **Rapid endotracheal intubation**. Used in **Electroconvulsive Shock Treatment (ECT)** to decrease pain and prevent injury. |

| **Key Side Effects** | **Malignant Hyperthermia (MH):** Triggered when used with **Halothane** in genetically susceptible patients; leads to massive contraction and increased body temperature. **Succinylcholine Apnea:** Prolonged respiratory paralysis due to genetic deficiency or atypical plasma **pseudocholinesterase**. **Hyperkalemia:** Fasciculations release potassium into the blood, dangerous in patients with burns or trauma, risking cardiac arrest. Increased **Intraocular Pressure**, Increased **Intragastric Pressure**, and **Postoperative muscle pain** (all caused by initial fasciculations). |

| **Cautions/Contraindications** | The block **cannot be reversed** by anticholinesterases. **Succinylcholine Apnea** requires artificial ventilation and infusion of **Fresh Frozen Plasma** (to supply the enzyme) as **no antidote is available**. MH treatment requires rapid cooling and **Dantrolene**. |

***

### Group 3: Spasmolytics (Centrally Acting)

| Point | Detail |

| :--- | :--- |

| **Generic/Brand Name** | **Diazepam**, **Baclofen**, **Tizanidine**, Chlorzoxazone. |

| **Classification** | **Spasmolytics**. **Centrally acting**. Reduce spasticity/hypertonia in neurologic conditions **without affecting normal tone**. |

| **MOA** | **Diazepam:** Acts at **$\text{GABA}_{\text{A}}$ receptors** in the CNS. **Baclofen:** Acts at **$\text{GABA}_{\text{B}}$ receptors**, causing hyperpolarization by reducing calcium influx; also inhibits the release of **Substance P** in the spinal cord. **Tizanidine:** Related to clonidine, acts as an **$\text{Alpha}_2$ agonist**. |

| **Clinical Uses** | Used in a variety of neurologic conditions. Baclofen can be given **intrathecally** and can reduce craving in alcoholics and treat migraine. |

| **Key Side Effects** | **Diazepam is Sedative**. Baclofen is **less sedative** but can cause drowsiness. |

| **Cautions/Contraindications** | N/A. |

***

### Group 4: Spasmolytics (Directly Acting)

| Point | Detail |

| :--- | :--- |

| **Generic/Brand Name** | **Dantrolene**. |

| **Classification** | **Spasmolytic**. **Directly acting skeletal muscle relaxant**. |

| **MOA** | Interferes with excitation-contraction coupling. Binds with the **Ryanodine Receptor ($\text{RyR}$) channel** of the sarcoplasmic reticulum, **inhibiting the release of activator calcium**. |

| **Clinical Uses** | **Drug of choice in malignant hyperthermia (MH)**. Used to reduce rigidity in spastic disorders. |

| **Key Side Effects** | Can cause **weakness, sedation, and hepatitis**. |

| **Cautions/Contraindications** | In MH treatment, it must be used alongside rapid cooling and correcting acidosis. |

***

### Group 5: Pre-synaptically Acting Agents

| Point | Detail |

| :--- | :--- |

| **Generic/Brand Name** | **Botulinum Toxin (Botox)**. **Inhibitors of Ach synthesis/storage/release:** Procaine (local anesthetic), Vesamicol, Hemicholinium, Triethylcholine. |

| **Classification** | Drugs that act **Pre-synaptically (pre-junctional)** by interfering with the synthesis and/or release of Ach. |

| **MOA** | **Botulinum Toxin** **inhibits acetylcholine release**. **Procaine** (local anesthetic) also inhibits Ach release. **Vesamicol** inhibits Ach storage. **Hemicholinium** inhibits Ach uptake (synthesis). **Triethylcholine** inhibits Ach utilization (synthesis). |

| **Clinical Uses** | Botox is used for **ophthalmic purposes**, **local muscle spasms**, and the **cosmetic treatment of facial wrinkles**. |

| **Key Side Effects** | Food poisoning (botulism) caused by the bacteria can result, within 12-36 hours, in **diplopia, dysphagia, dysarthria, and dyspnea**. |

| **Cautions/Contraindications** | Ach release is also inhibited by **excess $\text{Mg}^{++}$** and **lack of $\text{Ca}^{++}$**. |

***

### Related Agents: Drugs Used in Myasthenia Gravis (MG)

| Point | Detail |

| :--- | :--- |

| **Generic/Brand Name** | **Anticholinesterases:** Neostigmine, Pyridostigmine, Edrophonium. **Others:** Atropine, Cortisol, Ephedrine, Caffeine. |

| **Classification** | Agents used for the diagnosis and medical management of MG (an autoimmune disease involving antibodies against nicotinic receptors). |

| **MOA** | **Anticholinesterases** increase Ach at both nicotinic (N) and muscarinic (M) sites. **Atropine** is used to block unwanted muscarinic actions (e.g., bradycardia). **Cortisol** decreases antibody formation. **Caffeine** and **Ephedrine** potentiate Neostigmine's effect. |

| **Clinical Uses** | **Diagnosis:** Established using Edrophonium or Neostigmine + Atropine. **Management:** Anticholinesterases, Cortisol, Plasmapharesis (to wash antibodies), and Thymectomy. |

| **Key Side Effects** | N/A (Focus is on management). |

| **Cautions/Contraindications** | Medications with skeletal muscle relaxant effects (such as **Aminoglycoside antibiotics** and **Beta-blockers**) should be avoided as they can precipitate a severe MG attack. Atropine must precede Neostigmine to avoid severe muscarinic side effects. |